<p>OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - 獲取免費報告) 的股票在週四下跌了 15.5%。該股最低交易價為$2.31，最後交易價為$2.39。在午盤交易中，共交易了 320,302 股，較平均交易量 151,711 股增加了 111%。該股此前收盤價為$2.83。</p>
<h2>分析師評級變動</h2>
<p>多位股票分析師最近對該股發佈了報告。HC Wainwright 在 9 月 23 日的研究報告中重申了 “買入” 評級，並設定了$7.00 的目標價。Weiss Ratings 在 10 月 8 日的報告中重申了對 OKYO Pharma 的 “賣出（d-）” 評級。最後，B. Riley 在 12 月 8 日的研究報告中開始覆蓋 OKYO Pharma，給予 “買入” 評級，並設定了$5.00 的目標價。兩位投資分析師給予該股 “買入” 評級，一位給予 “持有” 評級，一位給予 “賣出” 評級。根據 MarketBeat.com 的數據，該公司的共識評級為 “持有”，共識目標價為$6.00。</p>
<p><strong>查看我們關於 OKYO 的最新報告</strong></p>
<h2>OKYO Pharma 價格表現</h2>
<p>該股的 50 日移動平均價為$2.16，200 日移動平均價為$2.37。</p>
<h2>機構投資者對 OKYO Pharma 的看法</h2>
<p>一家對沖基金最近在 OKYO Pharma 股票中購買了新股份。根據其最近向 SEC 提交的 13F 文件，Wealth Enhancement Advisory Services LLC 在第二季度收購了 OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - 免費報告) 的新股份。該公司收購了 10,000 股，價值約$28,000。機構投資者和對沖基金持有該公司 2.97% 的股份。</p>
<h2>關於 OKYO Pharma</h2>
<p>(獲取免費報告)</p>
<p>Okyo Pharma Inc 是一家臨牀階段的生物製藥公司，專注於開發用於治療炎症和纖維化疾病的新療法。該公司的產品線基於專有的 Fc 融合技術，旨在調節與糖尿病腎病和慢性移植物抗宿主病等疾病相關的免疫反應。Okyo Pharma 旨在通過針對與組織炎症和纖維化相關的關鍵細胞因子通路來解決重大的未滿足醫療需求。</p>
<p>Okyo Pharma 的主要產品候選藥物 OK-101 是一種 Fc 融合蛋白，目前正在進行糖尿病腎病的二期開發。</p>
<h2>另請參閲</h2>
<ul>
<li>我們更看好的五隻股票，勝過 OKYO Pharma</li>
<li>Elon 將 SpaceX 上市！$100 的首次公開募股機會！</li>
<li>家族信託如何幫助保護您的財富</li>
<li>一項價值數萬億的美國 “出生權” 索賠 - 靜悄悄地激活</li>
<li>執行命令 14330：特朗普最大的命令</li>
<li>崩盤已經開始（大多數人只是還沒看到）</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>您現在應該投資$1,000 在 OKYO Pharma 嗎？</h2>
<p>在您考慮 OKYO Pharma 之前，您需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦，現在購買，以便在更廣泛的市場注意到之前...而 OKYO Pharma 並不在名單上。</p>
<p>雖然 OKYO Pharma 目前在分析師中獲得 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

OKYO

<p>OKYO Pharma（納斯達克代碼：OKYO）股價下跌 15.5%，至 2.39 美元，交易量增加了 111%。分析師的評級意見不一：HC Wainwright 維持 “買入” 評級，目標價為 7.00 美元，而 Weiss Ratings 則給予 “賣出（d-）” 評級。市場共識評級為 “持有”，目標價為 6.00 美元。機構投資者持有該股票的 2.97%，該公司專注於開發針對炎症性疾病的療法。其主要候選藥物 OK-101 正在進行針對糖尿病腎病治療的第二階段臨牀試驗</p>

<p>OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) shares fell 15.5% on Thursday . The stock traded as low as $2.31 and last traded at $2.39. 320,302 shares were traded during mid-day trading, an increase of 111% from the average session volume of 151,711 shares. The stock had previously closed at $2.83.</p>
<div class="lb-trans"><p>OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - 獲取免費報告) 的股票在週四下跌了 15.5%。該股最低交易價為$2.31，最後交易價為$2.39。在午盤交易中，共交易了 320,302 股，較平均交易量 151,711 股增加了 111%。該股此前收盤價為$2.83。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><p>A number of equities analysts have recently issued reports on the stock. HC Wainwright reissued a &#34;buy&#34; rating and set a $7.00 price objective on shares of OKYO Pharma in a research report on Tuesday, September 23rd. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of OKYO Pharma in a report on Wednesday, October 8th. Finally, B. Riley began coverage on OKYO Pharma in a research note on Monday, December 8th. They issued a &#34;buy&#34; rating and a $5.00 price objective for the company. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of &#34;Hold&#34; and a consensus target price of $6.00.</p>
<div class="lb-trans"><p>多位股票分析師最近對該股發佈了報告。HC Wainwright 在 9 月 23 日的研究報告中重申了 “買入” 評級，並設定了$7.00 的目標價。Weiss Ratings 在 10 月 8 日的報告中重申了對 OKYO Pharma 的 “賣出（d-）” 評級。最後，B. Riley 在 12 月 8 日的研究報告中開始覆蓋 OKYO Pharma，給予 “買入” 評級，並設定了$5.00 的目標價。兩位投資分析師給予該股 “買入” 評級，一位給予 “持有” 評級，一位給予 “賣出” 評級。根據 MarketBeat.com 的數據，該公司的共識評級為 “持有”，共識目標價為$6.00。</p>
</div><p><strong>View Our Latest Report on OKYO</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 OKYO 的最新報告</strong></p>
</div><h2>OKYO Pharma Price Performance</h2>
<div class="lb-trans"><h2>OKYO Pharma 價格表現</h2>
</div><p>The stock's fifty day moving average is $2.16 and its two-hundred day moving average is $2.37.</p>
<div class="lb-trans"><p>該股的 50 日移動平均價為$2.16，200 日移動平均價為$2.37。</p>
</div><h2>Institutional Investors Weigh In On OKYO Pharma</h2>
<div class="lb-trans"><h2>機構投資者對 OKYO Pharma 的看法</h2>
</div><p>A hedge fund recently bought a new stake in OKYO Pharma stock. Wealth Enhancement Advisory Services LLC acquired a new stake in shares of OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Free Report) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm acquired 10,000 shares of the company's stock, valued at approximately $28,000. Institutional investors and hedge funds own 2.97% of the company's stock.</p>
<div class="lb-trans"><p>一家對沖基金最近在 OKYO Pharma 股票中購買了新股份。根據其最近向 SEC 提交的 13F 文件，Wealth Enhancement Advisory Services LLC 在第二季度收購了 OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - 免費報告) 的新股份。該公司收購了 10,000 股，價值約$28,000。機構投資者和對沖基金持有該公司 2.97% 的股份。</p>
</div><h2>About OKYO Pharma</h2>
<div class="lb-trans"><h2>關於 OKYO Pharma</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>Okyo Pharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory and fibrotic diseases. The company's pipeline is built on proprietary Fc-fusion technology designed to modulate immune responses associated with conditions such as diabetic nephropathy and chronic graft-versus-host disease. Okyo Pharma seeks to address significant unmet medical needs by targeting key cytokine pathways involved in tissue inflammation and fibrosis.</p>
<div class="lb-trans"><p>Okyo Pharma Inc 是一家臨牀階段的生物製藥公司，專注於開發用於治療炎症和纖維化疾病的新療法。該公司的產品線基於專有的 Fc 融合技術，旨在調節與糖尿病腎病和慢性移植物抗宿主病等疾病相關的免疫反應。Okyo Pharma 旨在通過針對與組織炎症和纖維化相關的關鍵細胞因子通路來解決重大的未滿足醫療需求。</p>
</div><p>Okyo Pharma's lead product candidate, OK-101, is an Fc-fusion protein in Phase 2 development for the treatment of diabetic kidney disease.</p>
<div class="lb-trans"><p>Okyo Pharma 的主要產品候選藥物 OK-101 是一種 Fc 融合蛋白，目前正在進行糖尿病腎病的二期開發。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另請參閲</h2>
</div><ul>
<li>Five stocks we like better than OKYO Pharma</li>
<li>Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!</li>
<li>How a Family Trust May Be Able To Help Preserve Your Wealth</li>
<li>A U.S. “birthright” claim worth trillions - activated quietly</li>
<li>Executive Order 14330: Trump’s Biggest Yet</li>
<li>The Crash Has Already Started (Most Just Don’t See It Yet)</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過 OKYO Pharma</li>
<li>Elon 將 SpaceX 上市！$100 的首次公開募股機會！</li>
<li>家族信託如何幫助保護您的財富</li>
<li>一項價值數萬億的美國 “出生權” 索賠 - 靜悄悄地激活</li>
<li>執行命令 14330：特朗普最大的命令</li>
<li>崩盤已經開始（大多數人只是還沒看到）</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in OKYO Pharma Right Now?</h2>
<div class="lb-trans"><h2>您現在應該投資$1,000 在 OKYO Pharma 嗎？</h2>
</div><p>Before you consider OKYO Pharma, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考慮 OKYO Pharma 之前，您需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OKYO Pharma wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦，現在購買，以便在更廣泛的市場注意到之前...而 OKYO Pharma 並不在名單上。</p>
</div><p>While OKYO Pharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 OKYO Pharma 目前在分析師中獲得 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

OKYO Pharma（NASDAQ:OKYO）股價下跌 15.5% - 接下來會如何發展？